CQN-DC-CHENGDU-SCI-FI
Please replace the release dated December 19, 2021 with the following corrected version due to multiple revisions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211219005052/en/
The updated release reads:
CHENGDU WINS THE BID TO HOST 81ST WORLD SCIENCE FICTION CONVENTION (2023 WORLDCON)
Chengdu, China won the bid to host the 81st World Science Fiction Convention (the 2023 Worldcon) at DisCon III, the 2021 Worldcon in Washington DC on December 18, 2021 (Beijing time). The other three bidders were Nice, France, Memphis, USA and Winnipeg, Canada, but Nice and Memphis had withdrawn before the final voting.
The Worldcon is the top sci-fi cultural event around the globe. It is during this event that the Hugo Award, dubbed as the “Nobel Prize in the Science Fiction Circle” among sci-fi fans, is granted to recognize the best sci-fi and fantasy works of the year.
As the winner of the bid, Chengdu will be the first city in China and the second in Asia to host the Worldcon. In recent years, a wave of enthusiasm for sci-fi is rising in China, especially after Liu Cixin became the first-ever Chinese winner of Hugo Award for his science fiction novel The Three-Body Problem in 2015.
In China, Chengdu is regarded as the capital of science and fiction and a mecca for all sci-fi fans in the country, because it is home to the Science Fiction World magazine, the world’s best-selling science and fiction periodical. It was on this magazine that Liu Cixin’s The Three-Body Problem was first serialized.
“Over the past four decades, Chengdu has nurtured generations of science and fiction writers and fans. Lots of science and fiction groups have organized various exciting science and fiction activities in the city. Now, Chengdu is looking forward to a chance to welcome sci-fi fans from all over the world,” stated Chengdu Science Fiction Society (CSFS) in its bid filing to the Worldcon.
The 2023 Worldcon will be held in August 2023 at Chengdu Century City New International Convention & Exhibition Center. The venue consists of 17 halls measuring a total of 120,000 square meters.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211219005052/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release
Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres
GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release
The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are
Wolfspeed Achieves 300mm Silicon Carbide (SiC) Technology Breakthrough13.1.2026 14:00:00 CET | Press release
300mm SiC Technology, Enabling Scalable Platforms for AI Infrastructure, AR/VR, and Advanced Power DevicesAnnouncement highlights:Strategic Technology Milestone – Wolfspeed has produced a single crystal 300mm (12-inch) silicon carbide wafer, representing a major advancement in the evolution of silicon carbide technology and a critical enabler for emerging applications. Technology leadership for Next-Gen Applications – Backed by one of the industry’s largest and most foundational silicon carbide IP portfolios, with over 2,300 issued and pending patents worldwide, Wolfspeed is accelerating the commercialization of 300mm technology to power next-generation platforms including AI infrastructure, augmented reality/virtual reality (AR/VR) and advanced power devices. Strengthening U.S. Semiconductor Leadership & Supply Chain Resilience –The company’s vertically integrated supply chain, from crystal growth to advanced packaging, supports national goals around compound semiconductor independenc
ExaGrid’s FY 2025 Results—A Record Quarter and a Record Year for Company13.1.2026 14:00:00 CET | Press release
ExaGrid reports 20 consecutive quarters of positive P&L, EBITDA, and Free Cash Flow ExaGrid®, the industry’s only Tiered Backup Storage solution with AI-Powered Retention Time-Lock (RTL) that includes a non-network-facing tier (tiered air gap), Auto Detect & Guard, delayed deletes and immutability for ransomware recovery, today announced that it had record bookings and record revenue in the fourth quarter ending December 31, 2025, and had a record-year for bookings and revenue for 2025. ExaGrid broke many records in the quarter (Q4 2025), including: Record overall revenue and bookings Record revenue and bookings for new customers Record revenue and bookings for existing customer repeat orders Record 202 new logo customers in the quarter Record 88 six-figure new logo customers 3 seven-figure new logo customer deals In addition, ExaGrid had a record bookings and revenue year in 2025 and remained P&L, EBITDA, and free cash flow positive for the 20th consecutive quarter. The company is 100
Armis Secures Italy’s Primary Public Healthcare Provider for the City of Naples as Cyber Threats Increase13.1.2026 14:00:00 CET | Press release
Armis Centrix™ provides immediate and detailed insights on network-connected assets, supporting compliance with national and European regulatory requirements Armis, the cyber exposure management & security company, today announced that ASL Napoli 1 Centro, Italy’s primary public healthcare provider for the City of Naples, is securing its attack surface using Armis Centrix™, the Armis Cyber Exposure Management Platform. Prior to working with Armis, ASL Napoli 1 Centro did not have the tools or capabilities to monitor physical and virtual assets in real time, which posed a challenge for its security and compliance. Armis Centrix™ was deployed with a clear goal: to provide ASL Napoli 1 Centro with a comprehensive, real-time view of its connected biomedical inventory and the associated risks to the overall environment. “Time-to-value was practically immediate; Armis began delivering valuable information as soon as the system was activated and connected to our internal network,” said Fulvio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom